Literature DB >> 19274372

Efficacy of benznidazol treatment for asymptomatic chagasic patients from state of Rio Grande do Sul evaluated during a three years follow-up.

C D Fernandes1, F M Tiecher, M M Balbinot, D B Liarte, D Scholl, M Steindel, A Romanha.   

Abstract

The efficacy of benznidazol on the treatment of chagasic patients from the state of Rio Grande do Sul was evaluated during a three-year follow-up. A cohort of 80 asymptomatic chronic chagasic patients or blood bank donors (49 male and 31 female) was studied. Their ages varied from 17-42 years, with a mean and a median of 30 and 35 years, respectively. The 80 patients presented positive serology, hemoculture and polymerase chain reaction (PCR). They were treated with 5 mg/Kg benznidazol twice a day for 60 days. Serological, parasitological and PCR methods were used to evaluate response. Serology was performed using commercial ELISA and indirect immunofluorescence (IFI) tests, parasitemia was monitored by hemoculture in LIT medium and PCR with primers S35/S36 was used to amplify a Trypanosoma cruzi 330 bp kDNA repetitive sequence. PCR positivity of 240 seropositive individuals was compared using DNA preparations from whole blood/guanidine EDTA (GE), buffy-coat/GE and frozen buffy-coat. Fifty non-chagasic individuals were used as negative controls. PCR positivity was 86.7% for the frozen buffy-coat, 71.7% for the GE/buffy-coat and 69.2% for the GE/whole blood. The hemocultures became negative just after treatment and remained negative during the three years of follow-up. In the third year after treatment, 9/80 (11.3%) patients presented negative PCR and, from those, four also presented negative serological tests. Furthermore, a reduction in three serological titers was observed in 27/80 (33.8%) of the patients treated. Taken together, the results show that four of the 80 (5.0%) chronic chagasic patients from the state of Rio Grande do Sul were cured after treatment with benznidazol.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19274372     DOI: 10.1590/s0074-02762009000100004

Source DB:  PubMed          Journal:  Mem Inst Oswaldo Cruz        ISSN: 0074-0276            Impact factor:   2.743


  22 in total

1.  Changes in Trypanosoma cruzi-specific immune responses after treatment: surrogate markers of treatment efficacy.

Authors:  Susana A Laucella; Damián Pérez Mazliah; Graciela Bertocchi; María G Alvarez; Gretchen Cooley; Rodolfo Viotti; María C Albareda; Bruno Lococo; Miriam Postan; Alejandro Armenti; Rick L Tarleton
Journal:  Clin Infect Dis       Date:  2009-12-01       Impact factor: 9.079

2.  Successful treatment with posaconazole of a patient with chronic Chagas disease and systemic lupus erythematosus.

Authors:  María-Jesús Pinazo; Gerard Espinosa; Montserrat Gállego; Paulo Luis López-Chejade; Julio A Urbina; Joaquim Gascón
Journal:  Am J Trop Med Hyg       Date:  2010-04       Impact factor: 2.345

3.  Correlation between presence of Trypanosoma cruzi DNA in heart tissue of baboons and cynomolgus monkeys, and lymphocytic myocarditis.

Authors:  James N Mubiru; Alice Yang; Edward J Dick; Michael Owston; R Mark Sharp; Jane F VandeBerg; Robert E Shade; John L VandeBerg
Journal:  Am J Trop Med Hyg       Date:  2014-02-24       Impact factor: 2.345

4.  Chagas disease in non-endemic countries: epidemiology, clinical presentation and treatment.

Authors:  José A Pérez-Molina; Francesca Norman; Rogelio López-Vélez
Journal:  Curr Infect Dis Rep       Date:  2012-06       Impact factor: 3.725

5.  Posttherapeutic cure criteria in Chagas' disease: conventional serology followed by supplementary serological, parasitological, and molecular tests.

Authors:  G F Machado-de-Assis; A R Silva; V A L Do Bem; M T Bahia; O A Martins-Filho; J C P Dias; P Albajar-Viñas; R M Torres; M Lana
Journal:  Clin Vaccine Immunol       Date:  2012-06-27

Review 6.  Trypanocidal drugs for chronic asymptomatic Trypanosoma cruzi infection.

Authors:  Juan Carlos Villar; Juan Guillermo Perez; Olga Lucia Cortes; Adelina Riarte; Micah Pepper; Jose Antonio Marin-Neto; Gordon H Guyatt
Journal:  Cochrane Database Syst Rev       Date:  2014-05-27

Review 7.  Advances and challenges towards a vaccine against Chagas disease.

Authors:  Israel Quijano-Hernandez; Eric Dumonteil
Journal:  Hum Vaccin       Date:  2011-11-01

8.  Hydroxymethylnitrofurazone treatment in indeterminate form of chronic Chagas disease: Reduced intensity of tissue parasitism and inflammation-A histopathological study.

Authors:  Cauê B Scarim; Cleverton R de Andrade; João A da Rosa; Jean L Dos Santos; Chung M Chin
Journal:  Int J Exp Pathol       Date:  2018-10-15       Impact factor: 1.925

9.  A serological, parasitological and clinical evaluation of untreated Chagas disease patients and those treated with benznidazole before and thirteen years after intervention.

Authors:  Girley Francisco Machado-de-Assis; Glaucia Alessio Diniz; Roberto Araújo Montoya; João Carlos Pinto Dias; José Rodrigues Coura; George Luiz Lins Machado-Coelho; Pedro Albajar-Viñas; Rosália Morais Torres; Marta de Lana
Journal:  Mem Inst Oswaldo Cruz       Date:  2013-11       Impact factor: 2.743

10.  Feasibility, drug safety, and effectiveness of etiological treatment programs for Chagas disease in Honduras, Guatemala, and Bolivia: 10-year experience of Médecins Sans Frontières.

Authors:  Oliver Yun; M Angeles Lima; Tom Ellman; Wilma Chambi; Sandra Castillo; Laurence Flevaud; Paul Roddy; Fernando Parreño; Pedro Albajar Viñas; Pedro Pablo Palma
Journal:  PLoS Negl Trop Dis       Date:  2009-07-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.